Bionow | News

Precision neuroscience company Monument Therapeutics announces £1.5m funding to...

Apr 22nd 2024

Monument Therapeutics, a precision neuroscience company, today announced new funding of £1.5 million from a combination of equity investment and non-dilutive grant as part of the Innovate U...

Major funding extension to advance revolutionary long-acting therapeutic technol...

Apr 22nd 2024

Unitaid has awarded more than £6M of new funding to a University of Liverpool-led project aiming to improve the long-acting therapeutics available to treat or prevent tuberculosis, malaria ...

Drug Discovery and Advanced Therapeutics Innovation Lab

Feb 15th 2024

The University of Manchester is looking for businesses active in the Drug Discovery and Advanced Therapeutics field to join a sandpit event aimed at fostering academic-industry collaboration...

Aptamer Group signs two substantial new contracts

Jan 25th 2023

Contracts worth over £500,000 with the potential for downstream milestone and royalty/ licensing payments

£1.3M to develop new inhaled drug delivery platforms to treat viral and bacteri...

Mar 8th 2022

The University of Liverpool in partnership with the Liverpool School of Tropical Medicine have joined forces on a £1.3million research project to develop new inhaled drug delivery platforms...

Aptamer Group and WuXi AppTec Research Service Division collaborate to identify ...

Jul 22nd 2021

Aptamer Group Limited, the developer of Optimer™ therapeutics and diagnostics, and WuXi AppTec Research Service Division, an integrated chemistry and biology research platform, today annou...

LSTM receives multi million grant to improve product development for Infectious ...

Jul 16th 2020

LSTM has received a grant of £3.3million of the European Regional Development Fund to improve the product development in the formulation of infectious diseases therapeutics.

Atelerix Strengthens Its Leadership Team

Jun 26th 2020

Atelerix welcomes Steve Docksey as Executive Chair and Ed Wagena as Chief Operating Officer! Atelerix has significantly strengthened its leadership team with two experienced industry execut...

Innovative synthetic antibody (Aptamer) test for SARS Cov-2 in development at Ap...

Mar 30th 2020

This test will omit the need for lab-based PCR testing for the virus antigen, massively scaling up the number of SARS Cov-2 virus tests that can be conducted in a community setting, partner...

Corona Virus (COVID-19) Therapeutics: £10 Million Call for Rapid Deployment

Mar 20th 2020

Funding available for the development and testing of therapeutics to treat COVID-19.

Calling all therapeutics and diagnostics companies – grant funding opportunity

Feb 21st 2020

The European Innovative Medicines Initiative will launch a call for applications to address the Corona virus in early March

Blueberry Therapeutics receives clearance from the FDA to proceed with the clini...

Feb 3rd 2020

Blueberry Therapeutics has received an investigational new drug (IND) clearance from the Food and Drug Administration (FDA) to proceed with the clinical development of BB2603 for the treatme...

News